You are here

  • Home
  • Archive
  • Volume 30, Issue 5
  • Real-world outcomes of abiraterone and enzalutamide in first-line treatment of metastatic castration-resistant prostate cancer: which patients benefit most?

Article info

Article menu
Download PDFPDF
Original research
Real-world outcomes of abiraterone and enzalutamide in first-line treatment of metastatic castration-resistant prostate cancer: which patients benefit most?

Authors

  1. Correspondence to Macarena García Trevijano Cabetas, Hospital Pharmacy Department, La Paz University Hospital, Madrid 28046, Spain; macarena.garciatrevijano{at}salud.madrid.org
View Full Text

Citation

García Trevijano Cabetas M, Escario-Gómez M, González-Del Valle L, et al
Real-world outcomes of abiraterone and enzalutamide in first-line treatment of metastatic castration-resistant prostate cancer: which patients benefit most?
European Journal of Hospital Pharmacy 2023;30:268-272.

Publication history

  • Received March 16, 2021
  • Accepted September 28, 2021
  • First published October 7, 2021.
Online issue publication 
October 18, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© European Association of Hospital Pharmacists 2023. No commercial re-use. See rights and permissions. Published by BMJ.